SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Alibaba Shares Fall as AI Spending Hits Profit 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Add as a preferred source on Google
NEW YORK, May 04, 2018 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Tuesday, May 8, 2018 at 8:30am ET to discuss results for the first quarter of 2018 and provide a business outlook for the remainder of the year. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter 2018 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events. An audio recording of the conference call will also be available for replay on the Company’s website, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.
CONTACT:
Jenna Bosco
SVP, Corporate Communications
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]
